| Product Name | L-DOPA antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit polyclonal antibody to L-DOPAL Dopa is an intermediate in dopamine biosynthesis. Clinically, L Dopa is used in the management of Parkinson's disease. It is used as a prodrug to increase dopamine levels since it is able to cross the blood-brain barrier whereas dopamine itself cannot. Once L Dopa has entered the central nervous system (CNS), it is metabolised to dopamine by aromatic L amino acid decarboxylase. This also occurs in the peripheral tissues, causing adverse effects and decreasing the available dopamine to the CNS, so it is standard practice to co administer a peripheral DOPA decarboxylase inhibitor and often a catechol-O-methyl transferase (COMT) inhibitor. The antiserum was tested using the free floating PAP technique on rat dopaminergic areas. The anti-conjugated L-DOPA antibodies gave a good staining between 1/2000-1/5000 dilution in these areas. |
| Immunogen | Synthetic L-Dopa conjugated to BSA via glutaraldehyde |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | ELISA |
| We recommend the following starting dilutions: ELISA 1:5000 - 1:10000. Optimal concentration should be determined experimentally by the end user.: |
|
| Species Reactivity | Other |
| Concentration | 1mg/ml |
| Gene Synonyms | Stress-activated protein kinase jnk-1 antibod Stressactivated protein kinase jnk1 antibod L DOPA LDOPA |
|---|---|
| Target | L-DOPA |
| Tissue Specificity | NB100-65501 is specific for conjugated L-dihydroxyphenylalanine (L-DOPA). The following reactivites were determined by competition ELISA: L-Dopa-G-BSA (1), alpha-methyl-L-Dopa-G-BSA (1/2,200), 3-O-methyl-L-Dopa-G-BSA (1/50,000), Dopamine-G-BSA (>1/50,000), Noradrenaline-G-BSA (>1/50,000), Tyrosine-G-BSA (>1/50,000). *L-Dopa-G-BSA concentration/other conjugated catecholamine concentration at half displacement.L-Dopa is an amino acid that is converted to dopamine in the brain. It is often given to patients in order to alleviate some of the symptoms of Parkinson's disease as, unlike dopamine itself, it can cross the blood-brain barrier. |
| Application Notes | We recommend the following starting dilutions: ELISA 1:5000 - 1:10000. Optimal concentration should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Storage Buffer | Phosphate buffered saline, pH 7.2 |
